Curcumin and fennel essential oil improve symptoms and quality of life in patients with irritable bowel syndrome

Journal of Gastrointestinal and Liver Diseases

Volumn 25, Issue 2, 2016, Pages 151-157

  Portincasa, Piero ^a   Bonfrate, Leonilde ^a   Scribano, Maria Lia ^b   Kohn, Anna ^b   Caporaso, Nicola ^c   Festi, Davide ^d   Campanale, Maria Chiara ^e   Di Rienzo, Teresa ^e   Guarino, Maria ^c   Taddia, Martina ^d   Fogli, Maria Vittoria ^f   Grimaldi, Maria ^f   Gasbarrini, Antonio ^e  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^f Alfa Wassermann SpA   (Italy)

Author keywords

Abdominal pain; Bloating; Irritable bowel syndrome; Randomized placebo controlled study

Indexed keywords

CURCUMIN; ESSENTIAL OIL; FENNEL OIL; NUTRACEUTICAL; PLACEBO; ANTIINFLAMMATORY AGENT; DRUG COMBINATION; GASTROINTESTINAL AGENT; VEGETABLE OIL;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY ASSESSMENT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VISUAL ANALOG SCALE; ADOLESCENT; AGED; CHEMISTRY; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FOENICULUM; IRRITABLE BOWEL SYNDROME; ISOLATION AND PURIFICATION; ITALY; MEDICINAL PLANT; MIDDLE AGED; MULTICENTER STUDY; PHYTOTHERAPY; PSYCHOLOGY; REMISSION; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CURCUMIN; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FOENICULUM; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; ITALY; MALE; MIDDLE AGED; OILS, VOLATILE; PHYTOTHERAPY; PLANT OILS; PLANTS, MEDICINAL; QUALITY OF LIFE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84970023740     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143: 1179-1187. e1-3. doi: 10.1053/j.gastro.2012.08.002
2. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014; 109 Suppl 1: S2-S26. doi: 10.1038/ajg.2014.187
3. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32. doi: 10.1056/NEJMoa1004409
4. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29: 329-341. doi: 10.1111/j.1365-2036.2008.03881.x
5. Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for Irritable Bowel Syndrome with Diarrhea. New Engl J Med 2016; 374: 242-253. doi: 10.1056/NEJMoa1505180
6. Spanier JA, Howden CW, Jones MP. A systematic review of alternative therapies in the irritable bowel syndrome. Arch Intern Med 2003; 163: 265-274. doi: 10.1001/archinte.163.3.265
7. Liu JP, Yang M, Liu YX, Wei M, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006: CD004116. doi: 10.1002/14651858.CD004116.pub2
8. Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. Ann N Y Acad Sci 2005; 1056: 206-217. doi: 10.1196/annals.1352.010
9. Lubbad A, Oriowo MA, Khan I. Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. Mol Cell Biochem 2009; 322: 127-135. doi: 10.1007/s11010-008-9949-4
10. Billerey-Larmonier C, Uno JK, Larmonier N, et al. Protective effects of dietary curcumin in mouse model of chemically induced colitis are strain dependent. Inflamm Bowel Dis 2008; 14: 780-793. doi: 10.1002/ ibd.20348
11. Zhang M, Deng CS, Zheng JJ, Xia J. Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis. Acta Pharmacol Sin 2006; 27: 1071-1077. doi: 10.1111/j.1745-7254.2006.00322.x
12. Martelli L, Ragazzi E, di Mario F, et al. A potential role for the vanilloid receptor TRPV1 in the therapeutic effect of curcumin in dinitrobenzene sulphonic acid-induced colitis in mice. Neurogastroenterol Motil 2007; 19: 668-674. doi: 10.1111/j.1365-2982.2007.00928.x
13. Deguchi Y, Andoh A, Inatomi O, et al. Curcumin prevents the development of dextran sulfate Sodium (DSS)-induced experimental colitis. Dig Dis Sci 2007; 52: 2993-2998. doi: 10.1007/s10620-006-9138-9
14. Ukil A, Maity S, Karmakar S, Datta N, Vedasiromoni JR, Das PK. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 2003; 139: 209-218. doi: 10.1038/sj.bjp.0705241
15. Sugimoto K, Hanai H, Tozawa K, et al. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 2002; 123: 1912-1922. doi: 10.1053/gast.2002.37050
16. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 2013; 15: 195-218. doi: 10.1208/s12248-012-9432-8
17. Epstein J, Docena G, MacDonald TT, Sanderson IR. Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. Br J Nutr 2010; 103: 824-832. doi: 10.1017/S0007114509992510
18. Larmonier CB, Midura-Kiela MT, Ramalingam R, et al. Modulation of neutrophil motility by curcumin: implications for inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 503-515. doi: 10.1002/ ibd.21391
19. Jobin C, Bradham CA, Russo MP, et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 1999; 163: 3474-3483.
20. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4: 1502-1506. doi: 10.1016/j.cgh.2006.08.008
21. Bundy R, Walker AF, Middleton RW, Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complement Med 2004; 10: 1015-1018. doi: 10.1089/acm.2004.10.1015
22. Ostad SN, Soodi M, Shariffzadeh M, Khorshidi N, Marzban H. The effect of fennel essential oil on uterine contraction as a model for dysmenorrhea, pharmacology and toxicology study. J Ethnopharmacol 2001; 76: 299-304. doi: 10.1016/S0378-8741(01)00249-5
23. Boskabady MH, Khatami A, Nazari A. Possible mechanism(s) for relaxant effects of Foeniculum vulgare on guinea pig tracheal chains. Pharmazie 2004; 59: 561-564.
24. Amjad H, Jafary HA. Foeniculum vulgare therapy in irritable bowel syndrome. Am J Gastroenterol 2000; 95: 2491. doi: 10.1111/j.1572-0241.2000.02633.x
25. Irving GR, Karmokar A, Berry DP, Brown K, Steward WP. Curcumin: the potential for efficacy in gastrointestinal diseases. Best Pract Res Clin Gastroenterol 2011; 25: 519-534. doi: 10.1016/j.bpg.2011.09.005
26. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4: 807-818. doi: 10.1021/mp700113r
27. Cuomo J, Appendino G, Dern AS, et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod 2011; 74: 664-669. doi: 10.1021/np1007262
28. Ishihara S, Tada Y, Fukuba N, et al. Pathogenesis of irritable bowel syndrome-review regarding associated infection and immune activation. Digestion 2013; 87: 204-211. doi: 10.1159/000350054
29. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491. doi: 10.1053/j.gastro.2005.11.061
30. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997; 11: 395-402. doi: 10.1046/j.1365-2036.1997.142318000.x
31. Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998; 43: 400-411. doi: 10.1023/A:1018831127942
32. Spiegel B, Strickland A, Naliboff BD, Mayer EA, Chang L. Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol 2008; 103: 2536-2543. doi: 10.1111/j.1572-0241.2008.01997.x
33. Craig OF, Quigley EM. Current and emerging therapies for the management of functional gastrointestinal disorders. Ther Adv Chronic Dis 2011; 2: 87-99. doi: 10.1177/2040622310389507
34. Rajasekaran SA. Therapeutic potential of curcumin in gastrointestinal diseases. World J Gastrointest Pathophysiol 2011; 2: 1-14. doi: 10.4291/ wjgp.v2.i1.1
35. Yosifov DY, Kaloyanov KA, Guenova ML, et al. Alkylphosphocholines and curcumin induce programmed cell death in cutaneous T-cell lymphoma cell lines. Leuk Res 2014; 38: 49-56. doi: 10.1016/j.leukres.2013.10.011
36. Guenova ML, Michova A, Balatzenko GN, et al. A particular expression pattern of CD13 epitope 7H5 in chronic lymphocytic leukaemia-a possible new therapeutic target. Hematology 2012; 17: 132-139. doi: 10.1179/102453312X13376952196296
37. Alaikov T, Konstantinov SM, Tzanova T, Dinev K, Topashka-Ancheva M, Berger MR. Antineoplastic and anticlastogenic properties of curcumin. Ann N Y Acad Sci 2007; 1095: 355-370. doi: 10.1196/annals.1397.039
38. Yoncheva K, Kamenova K, Perperieva T, et al. Cationic triblock copolymer micelles enhance antioxidant activity, intracellular uptake and cytotoxicity of curcumin. Int J Pharm 2015; 490: 298-307. doi: 10.1016/j.ijpharm.2015.05.057
39. Jelezova I, Drakalska E, Momekova D, et al. Curcumin loaded pH-sensitive hybrid lipid/block copolymer nanosized drug delivery systems. Eur J Pharm Sci 2015; 78: 67-78. doi: 10.1016/j.ejps.2015.07.005
40. Shimouchi A, Nose K, Takaoka M, Hayashi H, Kondo T. Effect of dietary turmeric on breath hydrogen. Dig Dis Sci 2009; 54: 1725-1729. doi: 10.1007/s10620-008-0550-1
41. Aldini R, Budriesi R, Roda G, et al. Curcuma longa extract exerts a myorelaxant effect on the ileum and colon in a mouse experimental colitis model, independent of the anti-inflammatory effect. PLoS One 2012; 7: e44650. doi: 10.1371/journal.pone.0044650
42. Lu CL, Chang FY. Placebo effect in patients with irritable bowel syndrome. J Gastroenterol Hepatol 2011; 26 Suppl 3: 116-118. doi: 10.1111/j.1440-1746.2011.06651.x